Beating out market leaders in PhII, antibiotic-maker Allecra readies for Phase III trials
European biotech Allecra announced good news from the frontlines of its fight against multidrug-resistant gram-negative bacteria – some of the most dangerous superbugs around – after wrapping up a Phase II study of its investigational antibiotic.
The company’s lead antibiotic candidate, an extended spectrum β-lactamase inhibitor known as AAI101, met all of the study’s objectives, prepping Allecra to take the drug into Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.